GlassScriptPhysician profile
J Wesley Cook
NPI 1104814912
$9,305.64
in general payments reported to CMS, 2019-2025
30 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,518 · 2020: $1,521 · 2021: $2,919 · 2022: $2,198 · 2023: $320 · 2024: $497 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,469.80 | 2019-2022 | |
| Abbvie INC. | $1,701.56 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $1,250.46 | 2019-2024 | Rybelsus, Ozempic |
| Viiv Healthcare Company | $705.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $495.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $389.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.21 | 2019-2022 | |
| Allergan, INC. | $309.85 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $216.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $203.40 | 2021-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $184.60 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Biotech, INC. | $159.57 | 2019-2022 | |
| Pfizer INC. | $117.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $109.29 | 2024-2025 | Cobenfy |
| Glaxosmithkline, LLC. | $100.78 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $82.49 | 2025 | |
| Lilly USA, LLC | $69.51 | 2021-2022 | |
| Indivior INC. | $57.31 | 2019-2024 | Perseris |
| Janssen Products, LP | $56.98 | 2019-2021 | |
| Napo Pharmaceuticals INC | $56.20 | 2022 | |
| Clarus Therapeutics INC. | $41.97 | 2021 | |
| Exact Sciences Corporation | $31.41 | 2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $27.36 | 2019 | |
| Lundbeck LLC | $25.44 | 2024 | Rexulti |
| Uswm, LLC | $20.79 | 2021 | |
| Organon LLC | $19.16 | 2023 | Nexplanon |
| Kowa Pharmaceuticals America, INC. | $17.64 | 2021 | |
| Theratechnologies INC. | $13.56 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.